IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated

IO Biotech, Inc.

Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.
All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.
Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.
Audit of 2025 financials not completed; company will not file 10-K or any periodic reports.

item 1.03 item 2.04 item 5.02 item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-133331
form_type: 8-K
ticker: IOBTQ
cik: 0001865494
company_name: IO Biotech, Inc.
filed_at: 2026-03-31T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.604929+00:00
generated_at: 2026-05-15T08:14:11.465574+00:00
sec_items: ["1.03", "2.04", "5.02", "8.01"]
event_type: other_material
sentiment: negative
materiality_score: 1.0
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-133331
json_url: https://secwatch.observer/filing/0001193125-26-133331.json
markdown_url: https://secwatch.observer/filing/0001193125-26-133331.md
text_url: https://secwatch.observer/filing/0001193125-26-133331.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/0001193125-26-133331-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/d87973d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-133331

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.